Science & Climate

Your Daily Biotechnology Briefing

Gene editing, drug development, clinical trials, and the science of engineering biology. Get the latest biotechnology developments delivered to your inbox every morning. AI-powered, personalized, and grounded in real sources.

Today's Briefing
Tuesday, Jul 14, 2026

Biotech Sector Fuels AI Drug Discovery and Advances Clinical Pipelines

  • Chai Discovery, an AI-driven drug discovery startup, successfully secured $400 million in a Series C funding round on July 14, 2026, tripling its valuation to $3.8 billion from $1.3 billion in just seven months. This substantial investment follows existing collaborations with Eli Lilly and Pfizer, with an anticipated partnership with argenx to develop new antibodies using AI.

  • Biogen is moving its anti-tau drug, diranersen, into Phase 3 trials for Alzheimer's disease, a decision supported by positive results observed at a lower dose in its Phase 2 study, despite the trial missing its primary endpoint. This counterintuitive advancement underscores the ongoing commitment to the anti-tau approach in Alzheimer's research.

  • Avere Therapeutics is set to become a publicly listed company through a reverse merger with NextCure, securing $320 million in funding on July 14, 2026. This capital injection will support the development of its lead psoriasis drug, AVR-001, which was licensed from Chinese biotech Hansoh.

The Bottom Line

The biotechnology landscape is marked by robust investment in AI-powered drug discovery platforms and strategic corporate maneuvers, as companies push forward with clinical programs for complex diseases, even when faced with nuanced trial outcomes.

Get Biotechnology in your inbox every morning

Join readers who start their day with an AI-powered briefing on biotechnology and the topics they care about most — fully sourced and ready in 5 minutes.

Start your free trial

7-day free trial · No credit card required

1

Pick your topics

Biotechnology, plus anything else you follow

2

We research overnight

AI synthesizes real-time sources while you sleep

3

Read in 5 minutes

Cited, structured, no fluff — in your inbox every morning